The 3 Best Sectors to Buy for 2014

Here are three sectors to watch in the new year that may attract the most cash and boast the best stocks to buy in 2014. More 

Bull’s Eye Report: Gilead Sciences (GILD)

Despite its recent runup, Gilead Sciences (GILD) shows room for immediate upside. More 

How to Profit From Every Biotech Buyout

Amgen's acquisition of Onyx underscores the fact that one simple biotech investment may also be the best one. More 

Grab These 3 Short-Term ETF Bargains While They Last

Leadership in the ETF circles has been focused on the regional and larger banks, gold miners, Internet, biotech and restaurant funds. More 

Bull’s Eye Report: Biogen Idec (BIIB)

Biogen Idec (BIIB), along with others in the biotech space, is looking very strong, with momentum that puts it ahead of the pack. More 

Changing U.S. Demographics Mean a Decades-Long Healthcare Boom

The aging of America's boomers is a compelling macro trend at work. And there's no better way to play that trend than via these ETFs. More 

Bull’s Eye Report:Isis Pharmaceuticals (ISIS)

Biotechs are blowing up -- and ISIS Pharmaceuticals (ISIS) is showing an attractive buy right now with potential 12% upside. More